HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer

• DOI: 10.1200/jco.2003.04.008
• Publication Date: 2003-07-14T19:35:40Z
• Authors: Annalisa Volpi; Oriana Nanni; Franca De Paola; Anna Maria Granato; Annita Mangia; Franco Monti; Francesco Schittulli; Mario De Lena; Emanuela Scarpi; Paola Rosetti; Manlio Monti; Lorenzo Gianni; Dino Amadori; Angelo Paradiso
• Keywords: Adjuvant Therapy; Clinical Significance

We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, largest case series node-negative patients to date.The pure prognostic value expression was 529 treated locoregional therapy alone until early relapse. Proliferative activity evaluated as [3H]thymidine labeling index and by immunohistochemistry. All biologic determinations were conducted within context an intra- interlaboratory National Quality Control Program.HER-2 not related relapse-free survival overall a significant discriminant prognosis subgroup rapidly proliferating tumors. Six-year rate relapse 40% for highly (> or =30%) positive tumors 26% those weakly HER-2-expressing (P =.039).HER-2 association proliferative identifies worst prognosis, who are candidates specific intensive adjuvant therapy.